VENLO, Netherlands,
July 27, 2017 /PRNewswire/ --
- Strong Q2 2017 results reaffirm QIAGEN on
track to achieve full-year goals:
- Net sales $349.0
million (+4% actual); adjusted net sales
$349.6
million (+5% actual, +7% CER vs.
+5-6% CER guidance)
- EPS $0.06; adjusted EPS
$0.25 ($0.25 CER), adjusted EPS
excluding restructuring charge $0.30 ($0.30 CER vs. $0.28-0.29 CER
guidance)
- H1 free cash flow of $91.6
million impacted by $30.8
million for restructuring
- Sample to Insight portfolio momentum with expansion of
QuantiFERON latent TB test, Personalized Healthcare, NGS portfolio
and QIAsymphony platform
- QIAGEN upgrades 2017 adjusted
sales outlook after solid H1, now expects 7% CER
growth; keeps adjusted EPS target before
restructuring of $1.25-1.27 CER
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA)
announced results of operations for the second quarter and first
half of 2017, delivering on goals for improvements in net sales and
adjusted earnings.
"QIAGEN's performance for the second quarter of 2017 further
strengthens our confidence in achieving our full-year goals for
strong sales growth and a double-digit increase in adjusted
earnings per share, as our differentiated portfolio of Sample to
Insight molecular testing solutions gains momentum," said
Peer M. Schatz, Chief Executive
Officer of QIAGEN N.V.
Click here for the full press release
http://corporate.qiagen.com/newsroom/press-releases/2017/2017-07-27-q2results
www.twitter.com/qiagen
www.facebook.com/QIAGEN
Download the QIAGEN Investor Relations App
Apple:
https://itunes.apple.com/us/app/qiagen-investor-relations/id1170201291?mt=8
Android:
https://play.google.com/store/apps/details?id=com.theirapp.qiagen&hl=de
Contacts
Investor Relations:
John Gilardi
Vice President Corporate Communications and Investor Relations
+49-2103-29-11711
+1-240-686-2222
Dr. Sarah Fakih
Associate Director Investor Relations
+49-2103-29-11457
Email: ir@qiagen.com
ir.qiagen.com
Public Relations:
Dr. Thomas Theuringer
Senior Director Public Relations and Digital Communications
+49-2103-29-11826
+1-240-686-7425
Email: pr@qiagen.com
pr.qiagen.com
SOURCE QIAGEN N.V.